MedTrace Logo

Effects of Rifaximin on Gut Microbiota and Emotion

NCT05587036 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-20

No results posted yet for this study

Summary

A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men.

Conditions

  • Healthy Volunteers
  • Stress
  • Fear

Interventions

DRUG

Rifaximin

Rifaximin oral tablet, 550 mg, twice daily, two-weeks

DIETARY_SUPPLEMENT

Placebo

Placebo oral tablet, twice daily, two-weeks

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Lukas Van Oudenhove, MD, PhD · KU Leuven

  • Kristin Verbeke, Pharm, PhD · KU Leuven

  • Boushra Dalile, PhD · KU Leuven

  • Jeroen Raes, PhD · VIB-KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587036 on ClinicalTrials.gov